| 1 | Reply | 6.2 | 0 | Citations (PDF) |
| 2 | Reply | 6.2 | 0 | Citations (PDF) |
| 3 | Design of the phase 3 <scp>MAESTRO</scp> clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis | 3.9 | 70 | Citations (PDF) |
| 4 | Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease | 3.6 | 73 | Citations (PDF) |
| 5 | The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction–associated steatotic liver disease and alcohol-associated liver disease | 4.7 | 85 | Citations (PDF) |
| 6 | Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study | 4.7 | 11 | Citations (PDF) |
| 7 | The impact of hepatitis B and C positive serologies on the outcomes of <scp>non‐hepatic</scp> solid organ transplantation in the United States | 2.1 | 1 | Citations (PDF) |
| 8 | Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease | 3.6 | 235 | Citations (PDF) |
| 9 | Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa | 4.1 | 73 | Citations (PDF) |
| 10 | A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | 43.7 | 1,346 | Citations (PDF) |
| 11 | Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action | 1.2 | 54 | Citations (PDF) |
| 12 | Food Insecurity, Low Household Income, and Low Education Level Increase the Risk of Having Metabolic Dysfunction–Associated Fatty Liver Disease Among Adolescents in the United States | 0.7 | 41 | Citations (PDF) |
| 13 | Review article: New developments in biomarkers and clinical drug development in alpha‐1 antitrypsin deficiency‐related liver disease | 3.9 | 10 | Citations (PDF) |
| 14 | The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes | 6.2 | 234 | Citations (PDF) |
| 15 | The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease | 4.8 | 22 | Citations (PDF) |
| 16 | Clinical and patient‐reported outcomes in patients with chronic hepatitis B and C and non‐alcoholic fatty liver disease from real‐world practices in Saudi Arabia, Turkey and Egypt | 2.1 | 4 | Citations (PDF) |
| 17 | Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction–associated steatohepatitis | 4.7 | 16 | Citations (PDF) |
| 18 | Validation of a Primary Biliary Cholangitis–Specific Version of Chronic Liver Disease Questionnaire: CLDQ-PBC | 2.9 | 7 | Citations (PDF) |
| 19 | MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials | 7.6 | 20 | Citations (PDF) |
| 20 | Review article: Hepatic steatosis and its associations with acute and chronic liver diseases | 3.9 | 15 | Citations (PDF) |
| 21 | Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis ‐ prevalence, clinical impact, economic implications and management strategies | 3.9 | 24 | Citations (PDF) |
| 22 | Liver Transplantation Profile Among Teenagers in the United States | 2.8 | 1 | Citations (PDF) |
| 23 | Estimating the economic impact of comorbidities in patients with MASH and defining high-cost burden in patients with noncirrhotic MASH | 4.7 | 9 | Citations (PDF) |
| 24 | Alcohol and Metabolic Syndrome Interaction | 3.7 | 1 | Citations (PDF) |
| 25 | Changes in mortality due to Chronic Liver Diseases (CLD) during the COVID-19 pandemic: Data from the United States’ National Vital Statistics System | 2.4 | 4 | Citations (PDF) |
| 26 | Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials | 6.2 | 21 | Citations (PDF) |
| 27 | The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression | 6.2 | 13 | Citations (PDF) |
| 28 | Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice | 4.8 | 29 | Citations (PDF) |
| 29 | Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis | 21.2 | 81 | Citations (PDF) |
| 30 | Securing wider EU commitment to the elimination of hepatitis C virus | 4.1 | 12 | Citations (PDF) |
| 31 | Impairment of patient‐reported outcomes among patients with non‐alcoholic fatty liver disease: a registry‐based study | 3.9 | 17 | Citations (PDF) |
| 32 | Vigorous physical activity provides protection against all‐cause deaths among adults patients with nonalcoholic fatty liver disease (<scp>NAFLD</scp>) | 3.9 | 50 | Citations (PDF) |
| 33 | Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores | 3.6 | 164 | Citations (PDF) |
| 34 | A practical use of noninvasive tests in clinical practice to identify high‐risk patients with nonalcoholic steatohepatitis | 3.9 | 29 | Citations (PDF) |
| 35 | The Growing Economic and Clinical Burden of Nonalcoholic Steatohepatitis (NASH) in the United States | 2.5 | 63 | Citations (PDF) |
| 36 | Clinical and patient‐reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™ | 2.1 | 14 | Citations (PDF) |
| 37 | Nonalcoholic Fatty Liver Disease Is Independently Associated With Higher All-Cause and Cause-Specific Mortality | 6.2 | 21 | Citations (PDF) |
| 38 | The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review | 10.6 | 2,352 | Citations (PDF) |
| 39 | Nonalcoholic Fatty Liver Disease: Disease Burden and Disease Awareness | 3.7 | 27 | Citations (PDF) |
| 40 | Development and validation of a primary sclerosing cholangitis-specific health-related quality of life instrument: CLDQ-PSC | 4.7 | 16 | Citations (PDF) |
| 41 | Sarcopenia Among Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Is Associated With Advanced Fibrosis | 6.2 | 33 | Citations (PDF) |
| 42 | The use of current knowledge and non‐invasive testing modalities for predicting at‐risk non‐alcoholic steatohepatitis and assessing fibrosis | 4.1 | 17 | Citations (PDF) |
| 43 | Letter: should we abandon <scp>FIB</scp>‐4 to characterise noninvasively patients with <scp>NAFLD</scp>? Authors' reply | 3.9 | 0 | Citations (PDF) |
| 44 | The combination of the enhanced liver fibrosis and FIB‐4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease | 3.9 | 9 | Citations (PDF) |
| 45 | Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties | 3.6 | 118 | Citations (PDF) |
| 46 | Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.) | 1.6 | 9 | Citations (PDF) |
| 47 | The Global Burden of Liver Disease | 6.2 | 371 | Citations (PDF) |
| 48 | Lifestyle interventions in nonalcoholic fatty liver disease | 48.0 | 212 | Citations (PDF) |
| 49 | Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease in Endocrinology Clinics | 3.5 | 11 | Citations (PDF) |
| 50 | Impact of Type 2 Diabetes on the Outcomes of Solid Organ Transplantations in the U.S.: Data From a National Registry | 6.5 | 13 | Citations (PDF) |
| 51 | Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience | 5.4 | 69 | Citations (PDF) |
| 52 | Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life | 6.2 | 68 | Citations (PDF) |
| 53 | A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease | 6.2 | 98 | Citations (PDF) |
| 54 | Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis | 6.2 | 80 | Citations (PDF) |
| 55 | Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data | 4.7 | 43 | Citations (PDF) |
| 56 | Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection | 4.7 | 48 | Citations (PDF) |
| 57 | Liver Transplant Center Size and the Impact on Clinical Outcomes and Resource Utilization | 1.2 | 13 | Citations (PDF) |
| 58 | Serum Biomarkers are Associated With Atherosclerotic Cardiovascular Disease Among Patients With Nonalcoholic Fatty Liver Disease Undergoing Elective Angiography | 6.2 | 4 | Citations (PDF) |
| 59 | Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response | 6.2 | 17 | Citations (PDF) |
| 60 | The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States | 6.2 | 14 | Citations (PDF) |
| 61 | Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis | 10.6 | 125 | Citations (PDF) |
| 62 | Global burden of NAFLD and chronic liver disease among adolescents and young adults | 10.6 | 205 | Citations (PDF) |
| 63 | Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C | 1.6 | 64 | Citations (PDF) |
| 64 | Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study | 3.6 | 137 | Citations (PDF) |
| 65 | Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis | 1.0 | 98 | Citations (PDF) |
| 66 | Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry | 6.2 | 88 | Citations (PDF) |
| 67 | Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease | 0.7 | 74 | Citations (PDF) |
| 68 | Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD | 3.6 | 136 | Citations (PDF) |
| 69 | Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis | 3.5 | 27 | Citations (PDF) |
| 70 | Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients | 4.7 | 58 | Citations (PDF) |
| 71 | Outcomes of hospitalized patients with COVID-19 during the course of the pandemic in a fully integrated health system | 2.4 | 7 | Citations (PDF) |
| 72 | Interrelationship between physical activity and depression in nonalcoholic fatty liver disease | 2.3 | 12 | Citations (PDF) |
| 73 | Health-Related Quality of Life and Health Care Resource Utilization in Patients With Chronic Liver Disease and Primary Liver Cancer in the United States: Analysis of Medical Expenditure Panel Survey | 2.5 | 4 | Citations (PDF) |
| 74 | Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease? | 10.6 | 162 | Citations (PDF) |
| 75 | The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? | 3.6 | 219 | Citations (PDF) |
| 76 | Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score | 10.6 | 45 | Citations (PDF) |
| 77 | Service line care delivery model for COVID-19 patient-centric care | 1.1 | 4 | Citations (PDF) |
| 78 | Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD | 4.7 | 70 | Citations (PDF) |
| 79 | Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease Among Adults in the United States, 1999–2016 | 6.2 | 63 | Citations (PDF) |
| 80 | American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings | 3.5 | 818 | Citations (PDF) |
| 81 | The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes | 4.8 | 72 | Citations (PDF) |
| 82 | Association of Previous Gastric Bypass Surgery and Patient Outcomes in Alcohol-Associated Cirrhosis Hospitalizations | 2.3 | 9 | Citations (PDF) |
| 83 | Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world | 3.9 | 181 | Citations (PDF) |
| 84 | The impact of the COVID‐19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry | 4.7 | 6 | Citations (PDF) |
| 85 | Sarcopenia, healthy living, and mortality in patients with chronic liver diseases | 4.7 | 27 | Citations (PDF) |
| 86 | Severe impairment of <scp>patient‐reported</scp> outcomes in patients with chronic hepatitis C virus infection seen in <scp>real‐world</scp> practices across the world: Data from the global liver registry | 2.1 | 7 | Citations (PDF) |
| 87 | The impact of fatigue on mortality of patients with non‐alcoholic fatty liver disease: Data from National Health and nutrition examination survey 2005–2010 and 2017–2018 | 4.1 | 28 | Citations (PDF) |
| 88 | Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States | 6.2 | 487 | Citations (PDF) |
| 89 | Patient‐reported outcomes in patients with non‐alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire‐non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis | 2.7 | 39 | Citations (PDF) |
| 90 | Physical Activity, Measured Objectively, Is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease | 6.2 | 71 | Citations (PDF) |
| 91 | Health-related quality of life in Cuban patients with chronic liver disease: A real-world experience | 1.6 | 23 | Citations (PDF) |
| 92 | The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis | 1.0 | 100 | Citations (PDF) |
| 93 | Integrating Patient‐Reported Outcomes Within Routine Hepatology Care: A Prompt to Action | 10.6 | 14 | Citations (PDF) |
| 94 | AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review | 1.0 | 423 | Citations (PDF) |
| 95 | Development and validation of a hepatitis B‐specific health‐related quality‐of‐life instrument: CLDQ‐HBV | 2.1 | 24 | Citations (PDF) |
| 96 | NAFLD: Reporting Histologic Findings in Clinical Practice | 10.6 | 140 | Citations (PDF) |
| 97 | Major Histocompatibility Complex Class I-Related Chain A Alleles and Histology of Nonalcoholic Fatty Liver Disease | 4.7 | 5 | Citations (PDF) |
| 98 | Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease | 2.4 | 31 | Citations (PDF) |
| 99 | Recent Trends in the Global Burden of Hepatitis B Virus: 2007–2017 | 1.0 | 21 | Citations (PDF) |
| 100 | Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease Using Noninvasive Tests From Primary Care and Endocrinology Real-World Practices | 2.9 | 19 | Citations (PDF) |
| 101 | Hospice care utilisation among elderly patients who died with hepatocellular carcinoma in the United States | 4.8 | 11 | Citations (PDF) |
| 102 | Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis | 4.7 | 29 | Citations (PDF) |
| 103 | A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH | 10.6 | 169 | Citations (PDF) |
| 104 | Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B | 4.8 | 18 | Citations (PDF) |
| 105 | Reply | 6.2 | 2 | Citations (PDF) |
| 106 | Defining comprehensive models of care for NAFLD | 48.0 | 119 | Citations (PDF) |
| 107 | Preparing for the NASH Epidemic: A Call to Action | 6.5 | 42 | Citations (PDF) |
| 108 | Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007‐2016 | 4.7 | 71 | Citations (PDF) |
| 109 | Poor Awareness of Liver Disease Among Adults With NAFLD in the United States | 4.7 | 102 | Citations (PDF) |
| 110 | The impact of hepatocellular carcinoma diagnosis on patients' health‐related quality of life | 2.7 | 14 | Citations (PDF) |
| 111 | Association between Activity and Brain-Derived Neurotrophic Factor in Patients with Non-Alcoholic Fatty Liver Disease: A Data-Mining Analysis | 2.8 | 10 | Citations (PDF) |
| 112 | Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma | 4.8 | 138 | Citations (PDF) |
| 113 | Preparing for the NASH epidemic: A call to action | 4.2 | 13 | Citations (PDF) |
| 114 | Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study | 1.2 | 7 | Citations (PDF) |
| 115 | Preparing for the NASH Epidemic: A Call to Action | 1.0 | 96 | Citations (PDF) |
| 116 | Preparing for the NASH epidemic: A call to action | 9.5 | 36 | Citations (PDF) |
| 117 | Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease | 6.8 | 57 | Citations (PDF) |
| 118 | Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019 | 3.6 | 218 | Citations (PDF) |
| 119 | The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017 | 4.7 | 39 | Citations (PDF) |
| 120 | Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations | 0.7 | 94 | Citations (PDF) |
| 121 | Advancing the global public health agenda for NAFLD: a consensus statement | 48.0 | 608 | Citations (PDF) |
| 122 | Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported Outcomes | 5.4 | 9 | Citations (PDF) |
| 123 | Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection | 6.2 | 21 | Citations (PDF) |
| 124 | Epidemiology of chronic liver diseases in the USA in the past three decades | 21.2 | 461 | Citations (PDF) |
| 125 | Hypothetical treatment of patients with non‐alcoholic steatohepatitis: Potential impact on important clinical outcomes | 4.1 | 6 | Citations (PDF) |
| 126 | Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design | 1.6 | 120 | Citations (PDF) |
| 127 | Securing sustainable funding for viral hepatitis elimination plans | 4.1 | 32 | Citations (PDF) |
| 128 | The impact of modifiable risk factors on the long‐term outcomes of non‐alcoholic fatty liver disease | 3.9 | 51 | Citations (PDF) |
| 129 | Increased cancer rates in patients with chronic hepatitis C | 4.1 | 28 | Citations (PDF) |
| 130 | Among Medicare Patients With Hepatocellular Carcinoma, Non–alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality | 2.4 | 54 | Citations (PDF) |
| 131 | Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities | 4.7 | 89 | Citations (PDF) |
| 132 | Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality | 0.7 | 65 | Citations (PDF) |
| 133 | Abnormal cardiac and metabolic measures correlate significantly with lower performance and activity in overweight chronic liver disease | 2.2 | 1 | Citations (PDF) |
| 134 | Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes | 4.7 | 51 | Citations (PDF) |
| 135 | Significant knowledge gap about non-alcoholic fatty liver disease (NAFLD) in real-world practices: a global survey of hepatologists, gastroenterologists, endocrinologists and primary care physicians | 3.6 | 4 | Citations (PDF) |
| 136 | The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007‐2017 | 4.7 | 88 | Citations (PDF) |
| 137 | Decline in Annual Mortality of Hepatitis C Virus–Related Hepatocellular Carcinoma in the United States, From 2009 to 2018 | 1.0 | 26 | Citations (PDF) |
| 138 | Modelling the economic and clinical burden of non‐alcoholic steatohepatitis in East Asia: Data from Hong Kong | 3.1 | 44 | Citations (PDF) |
| 139 | Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials | 3.6 | 419 | Citations (PDF) |
| 140 | Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices | 3.9 | 86 | Citations (PDF) |
| 141 | Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD | 10.6 | 684 | Citations (PDF) |
| 142 | MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease | 1.0 | 2,797 | Citations (PDF) |
| 143 | Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S. | 6.5 | 145 | Citations (PDF) |
| 144 | Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006–2016 | 0.8 | 16 | Citations (PDF) |
| 145 | Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis | 1.0 | 895 | Citations (PDF) |
| 146 | Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States | 4.7 | 72 | Citations (PDF) |
| 147 | Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population | 4.5 | 39 | Citations (PDF) |
| 148 | Gamma glutamyltransferase and risk of dementia in prediabetes and diabetes | 3.5 | 17 | Citations (PDF) |
| 149 | Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease | 4.8 | 107 | Citations (PDF) |
| 150 | Epidemiology of Non-alcoholic Fatty Liver Disease in North America | 2.4 | 60 | Citations (PDF) |
| 151 | Management of nonalcoholic fatty liver disease in the Middle East | 4.8 | 22 | Citations (PDF) |
| 152 | Outcomes of liver transplantation by insurance types in the United States | 1.1 | 40 | Citations (PDF) |
| 153 | Letter: the use of Fibrosis‐4 score in primary care and diabetology practices—Occam's razor applied to advanced fibrosis screening. Authors' reply | 3.9 | 0 | Citations (PDF) |
| 154 | Viral eradication is required for sustained improvement of patient‐reported outcomes in patients with hepatitis C | 4.1 | 28 | Citations (PDF) |
| 155 | Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates | 6.2 | 710 | Citations (PDF) |
| 156 | Impact of Nonmalignant Portal Vein Thrombosis in Transplant Recipients With Nonalcoholic Steatohepatitis | 2.6 | 26 | Citations (PDF) |
| 157 | Primary Biliary Cholangitis in Medicare Population | 10.6 | 23 | Citations (PDF) |
| 158 | Changing Trends in Etiology‐Based and Ethnicity‐Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States | 10.6 | 179 | Citations (PDF) |
| 159 | Prevalence, mortality and healthcare utilization among Medicare beneficiaries with Hepatitis C in Haemodialysis units | 2.1 | 6 | Citations (PDF) |
| 160 | REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis | 1.6 | 117 | Citations (PDF) |
| 161 | Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials | 10.6 | 247 | Citations (PDF) |
| 162 | The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis | 3.6 | 1,898 | Citations (PDF) |
| 163 | Hepatocellular carcinoma and non-alcoholic fatty liver disease | 4.5 | 66 | Citations (PDF) |
| 164 | Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States | 4.7 | 199 | Citations (PDF) |
| 165 | Relationships among neurotransmitters, cytokines and cognitive performance for individuals with hepatitis C achieving sustained virologic response: A pilot study | 2.4 | 11 | Citations (PDF) |
| 166 | Sa1612 – Mortality Related to Non-Alcoholic Fatty Liver Disease is Increasing in the United States Over the Last Decade | 1.0 | 1 | Citations (PDF) |
| 167 | Reply | 6.2 | 1 | Citations (PDF) |
| 168 | A systematic literature review on the use of platelet transfusions in patients with thrombocytopenia | 1.4 | 20 | Citations (PDF) |
| 169 | Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States | 4.7 | 16 | Citations (PDF) |
| 170 | Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005–2016 | 4.5 | 82 | Citations (PDF) |
| 171 | Patient‐reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication | 4.1 | 27 | Citations (PDF) |
| 172 | Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease | 4.7 | 58 | Citations (PDF) |
| 173 | Trends in hospitalizations for chronic liver disease‐related liver failure in the United States, 2005‐2014 | 4.1 | 41 | Citations (PDF) |
| 174 | Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States | 2.4 | 103 | Citations (PDF) |
| 175 | Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis | 6.2 | 44 | Citations (PDF) |
| 176 | Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis | 6.2 | 79 | Citations (PDF) |
| 177 | The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials | 10.6 | 337 | Citations (PDF) |
| 178 | Resource Utilization and Outcomes of Medicare Recipients With Chronic Hepatitis B in the United States | 2.4 | 2 | Citations (PDF) |
| 179 | Disease Burden of Hepatocellular Carcinoma: A Global Perspective | 2.3 | 290 | Citations (PDF) |
| 180 | Cytokine balance is restored as patient‐reported outcomes improve in patients recovering from chronic hepatitis C | 4.1 | 7 | Citations (PDF) |
| 181 | Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease | 6.2 | 156 | Citations (PDF) |
| 182 | Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis | 2.4 | 17 | Citations (PDF) |
| 183 | Systematic review with meta‐analysis: extrahepatic manifestations in chronic hepatitis C virus‐infected patients in East Asia | 3.9 | 32 | Citations (PDF) |
| 184 | Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life | 0.7 | 48 | Citations (PDF) |
| 185 | Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial | 52.8 | 1,092 | Citations (PDF) |
| 186 | Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease | 1.3 | 11 | Citations (PDF) |
| 187 | A Comprehensive Review of Patient-reported Outcomes in Patients With Chronic Liver Diseases | 2.4 | 36 | Citations (PDF) |
| 188 | Implementation of Value-based Medicine (VBM) to Patients With Chronic Hepatitis C (HCV) Infection | 2.4 | 4 | Citations (PDF) |
| 189 | Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States | 10.6 | 190 | Citations (PDF) |
| 190 | Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis | 10.6 | 1,628 | Citations (PDF) |
| 191 | Factors Associated With Potential Progressive Course of Primary Biliary Cholangitis | 2.4 | 13 | Citations (PDF) |
| 192 | Long-term Effects of Treatment for Chronic HBV Infection on Patient-Reported Outcomes | 6.2 | 15 | Citations (PDF) |
| 193 | Prevalence and outcomes of non‐alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States | 4.1 | 55 | Citations (PDF) |
| 194 | Non-alcoholic fatty liver disease – A global public health perspective | 3.6 | 1,890 | Citations (PDF) |
| 195 | Diagnosis and Management of Primary Biliary Cholangitis | 0.7 | 176 | Citations (PDF) |
| 196 | Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population | 4.7 | 50 | Citations (PDF) |
| 197 | Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease | 4.1 | 50 | Citations (PDF) |
| 198 | Predictors of nonalcoholic steatohepatitis and significant fibrosis in non‐obese nonalcoholic fatty liver disease | 4.1 | 50 | Citations (PDF) |
| 199 | Nonalcoholic Fatty Liver is Contributing to the Increase in Cases of Liver Disease in US Emergency Departments | 2.4 | 3 | Citations (PDF) |
| 200 | Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis | 4.5 | 23 | Citations (PDF) |
| 201 | Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients | 2.3 | 9 | Citations (PDF) |
| 202 | Aerobic capacity and exercise performance in nonalcoholic fatty liver disease | 1.1 | 22 | Citations (PDF) |
| 203 | Importance of fatigue and its measurement in chronic liver disease | 4.8 | 71 | Citations (PDF) |
| 204 | Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study | 2.1 | 39 | Citations (PDF) |
| 205 | Quality of Life in Patients with Cirrhosis—Measurement and Clinical Impact | 0.7 | 2 | Citations (PDF) |
| 206 | Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe | 2.1 | 29 | Citations (PDF) |
| 207 | Real‐world use of elbasvir‐grazoprevir in patients with chronic hepatitis C: retrospective analyses from the <scp>TRIO</scp> network | 3.9 | 29 | Citations (PDF) |
| 208 | The Stomach as an Endocrine Organ: Expression of Key Modulatory Genes and Their Contribution to Obesity and Non-alcoholic Fatty Liver Disease (NAFLD) | 2.7 | 5 | Citations (PDF) |
| 209 | Patient-Reported Outcomes for Patients With Chronic Liver Disease | 6.2 | 16 | Citations (PDF) |
| 210 | Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis | 6.2 | 30 | Citations (PDF) |
| 211 | Improvement of hepatic fibrosis and patient‐reported outcomes in non‐alcoholic steatohepatitis treated with selonsertib | 4.1 | 82 | Citations (PDF) |
| 212 | Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation | 2.6 | 64 | Citations (PDF) |
| 213 | Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir | 6.2 | 27 | Citations (PDF) |
| 214 | Hospice care in Medicare patients with primary liver cancer: the impact on resource utilisation and mortality | 3.9 | 18 | Citations (PDF) |
| 215 | Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes | 5.4 | 23 | Citations (PDF) |
| 216 | Hepatitis C Virus–Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens | 3.8 | 24 | Citations (PDF) |
| 217 | The epidemiology of nonalcoholic steatohepatitis | 1.4 | 82 | Citations (PDF) |
| 218 | Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient-Reported Outcomes | 6.2 | 36 | Citations (PDF) |
| 219 | Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD) | 1.3 | 189 | Citations (PDF) |
| 220 | Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan | 2.1 | 20 | Citations (PDF) |
| 221 | In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered | 4.1 | 36 | Citations (PDF) |
| 222 | The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases | 10.6 | 6,141 | Citations (PDF) |
| 223 | Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France | 3.9 | 14 | Citations (PDF) |
| 224 | Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia | 2.1 | 12 | Citations (PDF) |
| 225 | Improved Outcomes in HCV Patients Following Liver Transplantation During the Era of Direct-Acting Antiviral Agents | 6.2 | 36 | Citations (PDF) |
| 226 | Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis | 3.7 | 105 | Citations (PDF) |
| 227 | Waist‐to‐calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes | 2.7 | 25 | Citations (PDF) |
| 228 | The efficacy of new antiviral regimens for hepatitis C infection: Evidence from a systematic review | 10.6 | 3 | Citations (PDF) |
| 229 | Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis | 10.6 | 377 | Citations (PDF) |
| 230 | Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis | 10.6 | 313 | Citations (PDF) |
| 231 | Prediction of Health Utility Scores in Patients with Chronic Hepatitis C Using the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) | 2.0 | 9 | Citations (PDF) |
| 232 | Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3 | 3.9 | 42 | Citations (PDF) |
| 233 | Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin | 2.1 | 26 | Citations (PDF) |
| 234 | The effect of interferon‐free regimens on health‐related quality of life in East Asian patients with chronic hepatitis C | 4.1 | 18 | Citations (PDF) |
| 235 | Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument | 10.6 | 37 | Citations (PDF) |
| 236 | Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease | 10.6 | 2,094 | Citations (PDF) |
| 237 | Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis | 1.6 | 4 | Citations (PDF) |
| 238 | Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis | 1.3 | 69 | Citations (PDF) |
| 239 | Exercise as an intervention for patients with end-stage liver disease | 1.3 | 20 | Citations (PDF) |
| 240 | Association of Parity in Patients with Chronic Liver Disease | 1.6 | 7 | Citations (PDF) |
| 241 | Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis | 3.5 | 17 | Citations (PDF) |
| 242 | Impact of Chronic Hepatitis B Infection on Patient-Reported Outcomes | 0.7 | 0 | Citations (PDF) |
| 243 | The comprehensive outcomes of hepatitis C virus infection: A multi‐faceted chronic disease | 2.1 | 32 | Citations (PDF) |
| 244 | Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality | 4.7 | 25 | Citations (PDF) |
| 245 | Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey | 2.4 | 28 | Citations (PDF) |
| 246 | The Clinical and Economic Burden of Nonalcoholic Steatohepatitis | 0.7 | 5 | Citations (PDF) |
| 247 | An exploratory study examining how nano-liquid chromatography–mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease | 7.5 | 14 | Citations (PDF) |
| 248 | Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis | 1.0 | 335 | Citations (PDF) |
| 249 | 559 - Factors Associated with Progressive Course of Patients with Primary Biliary Cholangitis in the United States: Data from a Large-Real World Database | 1.0 | 1 | Citations (PDF) |
| 250 | Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH) | 2.4 | 22 | Citations (PDF) |
| 251 | Response to the letter: Hepatitis C screening in opioid epidemics in the United States and societal perspectives | 4.1 | 0 | Citations (PDF) |
| 252 | Patient‐Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition | 10.6 | 51 | Citations (PDF) |
| 253 | Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health‐related quality of life in East Asian patients with hepatitis C virus infection | 2.1 | 17 | Citations (PDF) |
| 254 | Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016 | 2.1 | 18 | Citations (PDF) |
| 255 | The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options | 3.6 | 71 | Citations (PDF) |
| 256 | Cognitive Performance in Individuals With Non-Alcoholic Fatty Liver Disease and/or Type 2 Diabetes Mellitus | 3.0 | 44 | Citations (PDF) |
| 257 | Chronic kidney disease in patients with chronic hepatitis C virus infection | 0.7 | 2 | Citations (PDF) |
| 258 | Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis | 10.6 | 1,674 | Citations (PDF) |
| 259 | The epidemiologic characteristics, temporal trends, predictors of death, and discharge disposition in patients with a diagnosis of sepsis: A cross-sectional retrospective cohort study | 2.4 | 14 | Citations (PDF) |
| 260 | Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection | 3.6 | 80 | Citations (PDF) |
| 261 | A disease‐specific quality of life instrument for non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis: <scp>CLDQ</scp>‐<scp>NAFLD</scp> | 4.1 | 97 | Citations (PDF) |
| 262 | Long‐term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States | 2.1 | 16 | Citations (PDF) |
| 263 | Hepatitis C virus infection | 50.7 | 450 | Citations (PDF) |
| 264 | Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials | 3.0 | 19 | Citations (PDF) |
| 265 | Treatment of patients waitlisted for liver transplant with all‐oral direct‐acting antivirals is a cost‐effective treatment strategy in the United States | 10.6 | 27 | Citations (PDF) |
| 266 | Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy | 6.2 | 24 | Citations (PDF) |
| 267 | Hepatitis C Infection | 3.7 | 28 | Citations (PDF) |
| 268 | Economic Burden of Hepatitis C Infection | 3.7 | 64 | Citations (PDF) |
| 269 | Patient‐reported outcomes in patients co‐infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL‐5 study | 4.1 | 32 | Citations (PDF) |
| 270 | Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma | 2.3 | 24 | Citations (PDF) |
| 271 | Patient-Reported Outcomes and Fatigue in Patients with Chronic Hepatitis C Infection | 3.7 | 37 | Citations (PDF) |
| 272 | Hepatitis C Virus Infection Care Pathway—A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group | 1.0 | 10 | Citations (PDF) |
| 273 | The value of cure associated with treating treatment‐naïve chronic hepatitis C genotype 1: Are the new all‐oral regimens good value to society? | 4.1 | 16 | Citations (PDF) |
| 274 | Dermatologic Manifestations of Chronic Hepatitis C Infection | 3.7 | 29 | Citations (PDF) |
| 275 | Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study | 3.6 | 107 | Citations (PDF) |
| 276 | Long-Term Outcomes of Nonalcoholic Fatty Liver Disease: From Nonalcoholic Steatohepatitis to Nonalcoholic Steatofibrosis | 6.2 | 31 | Citations (PDF) |
| 277 | Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial) | 2.3 | 4 | Citations (PDF) |
| 278 | International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement | 7.5 | 96 | Citations (PDF) |
| 279 | Demographics, Resource Utilization, and Outcomes of Elderly Patients With Chronic Liver Disease Receiving Hospice Care in the United States | 0.7 | 24 | Citations (PDF) |
| 280 | Should adults with diabetes mellitus be vaccinated against hepatitis B virus? A systematic review of diabetes mellitus and the progression of hepatitis B disease | 3.2 | 28 | Citations (PDF) |
| 281 | Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients | 3.9 | 37 | Citations (PDF) |
| 282 | Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes | 2.3 | 213 | Citations (PDF) |
| 283 | Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis | 3.7 | 36 | Citations (PDF) |
| 284 | Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease | 4.7 | 116 | Citations (PDF) |
| 285 | Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities | 1.3 | 223 | Citations (PDF) |
| 286 | Superiority of Interferon-Free Regimens for Chronic Hepatitis C | 1.3 | 44 | Citations (PDF) |
| 287 | Demonstration of two types of fatigue in subjects with chronic liver disease using factor analysis | 2.1 | 14 | Citations (PDF) |
| 288 | The impact of hepatitis C virus outside the liver: Evidence from Asia | 4.1 | 41 | Citations (PDF) |
| 289 | Direct and Indirect Economic Burden of Chronic Liver Disease in the United States | 6.2 | 143 | Citations (PDF) |
| 290 | Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis | 6.2 | 76 | Citations (PDF) |
| 291 | Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis | 2.4 | 71 | Citations (PDF) |
| 292 | Fatigue and Hepatitis C: a focus group study | 0.3 | 4 | Citations (PDF) |
| 293 | Pediatric Non-Alcoholic Fatty Liver Disease | 1.7 | 54 | Citations (PDF) |
| 294 | Independent Predictors of Mortality and Resource Utilization in Viral Hepatitis Related Hepatocellular Carcinoma | 1.6 | 20 | Citations (PDF) |
| 295 | The Prevalence of Parkinson Disease Among Patients With Hepatitis C Infection | 1.6 | 12 | Citations (PDF) |
| 296 | Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention | 48.0 | 4,698 | Citations (PDF) |
| 297 | Rising Rate of Liver Transplantation in the Baby Boomer Generation with Non-alcoholic Steatohepatitis in the United States | 2.3 | 8 | Citations (PDF) |
| 298 | Trends in Liver Transplantation in Hepatitis C Virus–Infected Persons, United States | 3.9 | 2 | Citations (PDF) |
| 299 | Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review | 4.8 | 155 | Citations (PDF) |
| 300 | Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States | 1.3 | 13 | Citations (PDF) |
| 301 | Patient‐Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon‐ and Ribavirin‐Free Regimens | 2.9 | 37 | Citations (PDF) |
| 302 | The impact of ledipasvir/sofosbuvir on patient‐reported outcomes in cirrhotic patients with chronic hepatitis C: the <scp>SIRIUS</scp> study | 4.1 | 52 | Citations (PDF) |
| 303 | Vaccination against hepatitis A and B in patients with chronic liver disease and type 2 diabetes: has anything changed? | 4.1 | 9 | Citations (PDF) |
| 304 | Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir | 1.3 | 34 | Citations (PDF) |
| 305 | Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic <scp>HCV</scp> genotype 1‐infected treatment‐naive patients | 4.1 | 26 | Citations (PDF) |
| 306 | An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens | 0.7 | 86 | Citations (PDF) |
| 307 | Nonalcoholic Steatohepatitis and Liver Transplantation | 0.7 | 1 | Citations (PDF) |
| 308 | Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C | 2.3 | 12 | Citations (PDF) |
| 309 | The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH) | 2.0 | 32 | Citations (PDF) |
| 310 | Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial | 23.6 | 70 | Citations (PDF) |
| 311 | Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C | 1.5 | 6 | Citations (PDF) |
| 312 | Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C | 2.0 | 46 | Citations (PDF) |
| 313 | The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe | 10.6 | 1,110 | Citations (PDF) |
| 314 | International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement | 7.5 | 96 | Citations (PDF) |
| 315 | Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials | 5.4 | 57 | Citations (PDF) |
| 316 | Lower rates of receiving model for end‐stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma | 2.6 | 24 | Citations (PDF) |
| 317 | Long‐term outcomes of heart transplant recipients with hepatitis C positivity: the data from the U.S. transplant registry | 1.7 | 22 | Citations (PDF) |
| 318 | Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease | 2.6 | 49 | Citations (PDF) |
| 319 | Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease | 2.6 | 70 | Citations (PDF) |
| 320 | Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor | 2.4 | 27 | Citations (PDF) |
| 321 | The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV) | 1.3 | 7 | Citations (PDF) |
| 322 | Adherence to treatment of chronic hepatitis C | 1.3 | 70 | Citations (PDF) |
| 323 | Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir | 1.3 | 14 | Citations (PDF) |
| 324 | Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States | 1.3 | 32 | Citations (PDF) |
| 325 | Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes | 10.6 | 9,456 | Citations (PDF) |
| 326 | 603 Access to Therapy in Era of All DAA Regimens: Real-World Experience From the TRIO Network | 1.0 | 1 | Citations (PDF) |
| 327 | Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study | 2.4 | 20 | Citations (PDF) |
| 328 | Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL) | 3.0 | 128 | Citations (PDF) |
| 329 | Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies | 3.0 | 2 | Citations (PDF) |
| 330 | Mental and Emotional Impairment in Patients With Hepatitis C is Related to Lower Work Productivity | 3.0 | 20 | Citations (PDF) |
| 331 | Epidemiology and natural history of non-alcoholic fatty liver disease | 9.5 | 389 | Citations (PDF) |
| 332 | Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality | 1.0 | 303 | Citations (PDF) |
| 333 | Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden | 1.0 | 353 | Citations (PDF) |
| 334 | Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial | 3.6 | 105 | Citations (PDF) |
| 335 | Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World | 3.7 | 478 | Citations (PDF) |
| 336 | Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection | 6.2 | 58 | Citations (PDF) |
| 337 | Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin | 3.6 | 32 | Citations (PDF) |
| 338 | Perception of Effort During Activity in Patients With Chronic Hepatitis C and Nonalcoholic Fatty Liver Disease | 2.0 | 13 | Citations (PDF) |
| 339 | Underutilization of Living Donor Liver Transplantation in the United States: Bias against MELD 20 and Higher | 2.3 | 9 | Citations (PDF) |
| 340 | Treatment strategies for chronic hepatitis C prior to and following liver transplantation | 2.3 | 10 | Citations (PDF) |
| 341 | Reply to “Debilitating fatigue as a treatment indication in chronic hepatitis C” | 3.6 | 1 | Citations (PDF) |
| 342 | Overall health‐related quality of life in patients with end‐stage liver disease | 1.4 | 30 | Citations (PDF) |
| 343 | The price of shortening anti–hepatitis C virus therapy: Is this truly cost saving? | 1.4 | 3 | Citations (PDF) |
| 344 | Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis | 2.4 | 29 | Citations (PDF) |
| 345 | Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009 | 10.6 | 737 | Citations (PDF) |
| 346 | The outcomes of adult liver transplants in the United States from 1987 to 2013 | 4.1 | 32 | Citations (PDF) |
| 347 | <scp>HCV</scp> infection is associated with lower survival in simultaneous liver kidney transplant recipients in the United States | 1.7 | 7 | Citations (PDF) |
| 348 | Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States | 10.6 | 46 | Citations (PDF) |
| 349 | What is the ethical responsibility of a provider when prescribing the new direct‐acting antiviral agents to patients with hepatitis C infection? | 1.4 | 8 | Citations (PDF) |
| 350 | Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials | 10.6 | 129 | Citations (PDF) |
| 351 | Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States | 1.0 | 1,677 | Citations (PDF) |
| 352 | Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced <scp>HCV</scp> genotype 1 patients: <scp>REALIZE</scp> study | 4.1 | 6 | Citations (PDF) |
| 353 | Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes | 3.8 | 55 | Citations (PDF) |
| 354 | Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease | 3.7 | 84 | Citations (PDF) |
| 355 | The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment | 3.5 | 93 | Citations (PDF) |
| 356 | A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection | 3.6 | 52 | Citations (PDF) |
| 357 | Interferon-Free Regimens for Chronic Hepatitis C: Barriers Due to Treatment Candidacy and Insurance Coverage | 2.3 | 26 | Citations (PDF) |
| 358 | Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir | 3.6 | 154 | Citations (PDF) |
| 359 | Trends in Outpatient Resource Utilizations and Outcomes for Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease | 2.4 | 47 | Citations (PDF) |
| 360 | Anti‐adipocyte antibody response in patients with non‐alcoholic fatty liver disease | 2.7 | 7 | Citations (PDF) |
| 361 | Prevalence and determinants of fatty liver in normal-weight and overweight young adults. The Cardiovascular Risk in Young Finns Study | 4.1 | 42 | Citations (PDF) |
| 362 | Adipocytokine expression associated with miRNA regulation and diagnosis of NASH in obese patients with NAFLD | 4.1 | 25 | Citations (PDF) |
| 363 | Predictors of chronic liver disease in individuals with human immunodeficiency virus infection | 1.6 | 9 | Citations (PDF) |
| 364 | Survey of health status, nutrition and geography of food selection of chronic liver disease patients | 1.6 | 27 | Citations (PDF) |
| 365 | Statin use is not associated with liver related mortality | 1.6 | 13 | Citations (PDF) |
| 366 | Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects | 2.4 | 32 | Citations (PDF) |
| 367 | Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study | 2.0 | 31 | Citations (PDF) |
| 368 | A single non‐invasive model to diagnose non‐alcoholic fatty liver disease (<scp>NAFLD</scp>) and non‐alcoholic steatohepatitis (<scp>NASH</scp>) | 2.7 | 85 | Citations (PDF) |
| 369 | Markers of endothelial dysfunction in patients with non‐alcoholic fatty liver disease and coronary artery disease | 2.7 | 22 | Citations (PDF) |
| 370 | Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens | 10.6 | 79 | Citations (PDF) |
| 371 | Multiple Factors Predict Physical Performance in People with Chronic Liver Disease | 1.5 | 20 | Citations (PDF) |
| 372 | The Portrait of an Adult Liver Transplant Recipient in the United States From 1987 to 2013 | 10.8 | 40 | Citations (PDF) |
| 373 | Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study | 3.6 | 90 | Citations (PDF) |
| 374 | Effects of Sofosbuvir-Based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C | 6.2 | 88 | Citations (PDF) |
| 375 | Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C) | 3.6 | 90 | Citations (PDF) |
| 376 | Obesity-Associated Nonalcoholic Fatty Liver Disease | 3.7 | 86 | Citations (PDF) |
| 377 | Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients | 3.6 | 118 | Citations (PDF) |
| 378 | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study | 52.8 | 769 | Citations (PDF) |
| 379 | Hepatitis C Virus Infection and Coronary Artery Disease Risk: A Systematic Review of the Literature | 2.3 | 51 | Citations (PDF) |
| 380 | Expression of energy metabolism related genes in the gastric tissue of obese individuals with non-alcoholic fatty liver disease | 2.4 | 7 | Citations (PDF) |
| 381 | Host Genetic Variants in Obesity-Related Nonalcoholic Fatty Liver Disease | 3.7 | 11 | Citations (PDF) |
| 382 | Adipose Tissue as an Endocrine Organ | 3.7 | 173 | Citations (PDF) |
| 383 | A New Comorbidity Model for Predicting Mortality in Patients With Cirrhosis: Does It Work? | 1.0 | 9 | Citations (PDF) |
| 384 | Inpatient Economic and Mortality Assessment for Liver Transplantation | 1.2 | 19 | Citations (PDF) |
| 385 | Resource Utilization and Survival Among Medicare Patients with Advanced Liver Disease | 2.3 | 10 | Citations (PDF) |
| 386 | Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS) | 6.6 | 78 | Citations (PDF) |
| 387 | Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) | 2.3 | 272 | Citations (PDF) |
| 388 | Association of Sleep Disorders with Nonalcoholic Fatty Liver Disease (NAFLD): A Population-based Study | 2.5 | 50 | Citations (PDF) |
| 389 | Sustained virologic response rates with telaprevir by response after 4weeks of lead-in therapy in patients with prior treatment failure | 3.6 | 19 | Citations (PDF) |
| 390 | Expression of genes for micro<scp>RNA</scp>‐processing enzymes is altered in advanced non‐alcoholic fatty liver disease | 2.7 | 37 | Citations (PDF) |
| 391 | Comparison of activity level among patients with chronic liver disease | 2.6 | 10 | Citations (PDF) |
| 392 | In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not | 9.5 | 162 | Citations (PDF) |
| 393 | Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure | 3.6 | 52 | Citations (PDF) |
| 394 | Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial | 10.6 | 21 | Citations (PDF) |
| 395 | Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection | 43.7 | 1,651 | Citations (PDF) |
| 396 | Association of Chronic Liver Disease with Depression: A Population-Based Study | 3.0 | 93 | Citations (PDF) |
| 397 | Interaction of Type 2 diabetes and nonalcoholic fatty liver disease | 2.5 | 10 | Citations (PDF) |
| 398 | Expression of Inflammation-Related Genes Is Altered in Gastric Tissue of Patients with Advanced Stages of NAFLD | 3.8 | 5 | Citations (PDF) |
| 399 | The inpatient economic and mortality impact of hepatocellular carcinoma from 2005 to 2009: analysis of the US nationwide inpatient sample | 4.1 | 31 | Citations (PDF) |
| 400 | Current management of patients with nonalcoholic fatty liver disease | 3.1 | 3 | Citations (PDF) |
| 401 | Validation of the chronic liver disease questionnaire in Serbian patients | 4.8 | 17 | Citations (PDF) |
| 402 | Knowledge-Based Identification of Soluble Biomarkers: Hepatic Fibrosis in NAFLD as an Example | 2.4 | 15 | Citations (PDF) |
| 403 | Oral L-Ornithine-L-Aspartate Improves Health-Related Quality of Life in Cirrhotic Patients with Hepatic Encephalopathy | 2.2 | 31 | Citations (PDF) |
| 404 | The Intestinal Microbiota and Liver Disease | 1.5 | 46 | Citations (PDF) |
| 405 | Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States | 1.3 | 477 | Citations (PDF) |
| 406 | African Americans Are Less Likely to Have Clearance of Hepatitis C Virus Infection | 2.4 | 18 | Citations (PDF) |
| 407 | The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology | 1.0 | 1,655 | Citations (PDF) |
| 408 | Independent Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in the US Population | 6.2 | 318 | Citations (PDF) |
| 409 | Natural history of nonalcoholic fatty liver disease | 1.4 | 8 | Citations (PDF) |
| 410 | In-Hospital Mortality and Economic Burden Associated With Hepatic Encephalopathy in the United States From 2005 to 2009 | 6.2 | 207 | Citations (PDF) |
| 411 | Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease | 2.5 | 76 | Citations (PDF) |
| 412 | Disparities in Activity Level and Nutrition Between Patients With Chronic Hepatitis C and Blood Donors | 2.0 | 4 | Citations (PDF) |
| 413 | The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association | 0.7 | 381 | Citations (PDF) |
| 414 | Economic model of a birth cohort screening program for hepatitis C virus | 10.6 | 102 | Citations (PDF) |
| 415 | The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association | 10.6 | 3,167 | Citations (PDF) |
| 416 | Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C) | 2.5 | 12 | Citations (PDF) |
| 417 | The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin | 6.6 | 22 | Citations (PDF) |
| 418 | Potential mechanisms underlying the associations between liver enzymes and risk for type 2 diabetes | 10.6 | 9 | Citations (PDF) |
| 419 | Anthropometric and Clinical Factors Associated with Mortality in Subjects with Nonalcoholic Fatty Liver Disease | 2.3 | 61 | Citations (PDF) |
| 420 | Quality of Life in Cirrhosis | 2.7 | 75 | Citations (PDF) |
| 421 | Telaprevir for Retreatment of HCV Infection | 43.7 | 1,478 | Citations (PDF) |
| 422 | Protein Pathway Activation Associated with Sustained Virologic Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV) | 3.5 | 10 | Citations (PDF) |
| 423 | Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008 | 6.2 | 980 | Citations (PDF) |
| 424 | Depression in Patients with Nonalcoholic Fatty Liver Disease and Chronic Viral Hepatitis B and C | 3.0 | 132 | Citations (PDF) |
| 425 | Biomarkers for Non-invasive Diagnosis of Non-alcoholic Steatohepatitis | 2.4 | 0 | Citations (PDF) |
| 426 | Association of Obestatin, Ghrelin, and Inflammatory Cytokines in Obese Patients with Non-alcoholic Fatty Liver Disease | 2.4 | 55 | Citations (PDF) |
| 427 | Non-Invasive markers for hepatic fibrosis | 2.4 | 248 | Citations (PDF) |
| 428 | Insurance status and treatment candidacy of hepatitis C patients: Analysis of population-based data from the United States | 10.6 | 85 | Citations (PDF) |
| 429 | Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality | 10.6 | 574 | Citations (PDF) |
| 430 | Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population | 10.6 | 38 | Citations (PDF) |
| 431 | Novel treatment strategies for patients with nonalcoholic fatty liver disease | 0.3 | 7 | Citations (PDF) |
| 432 | Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS) | 1.8 | 67 | Citations (PDF) |
| 433 | Hepatic Gene Expression of Caucasian and African-American Patients with Obesity-Related Non-Alcoholic Fatty Liver Disease | 2.4 | 55 | Citations (PDF) |
| 434 | Validation of endogenous reference genes for qRT-PCR analysis of human visceral adipose samples | 4.1 | 99 | Citations (PDF) |
| 435 | A Methodology for Successfully Producing Global Translations of Patient Reported Outcome Measures for Use in Multiple Countries | 2.0 | 31 | Citations (PDF) |
| 436 | Response to the Letter from Ms. Tamzin Furtado | 2.0 | 1 | Citations (PDF) |
| 437 | Non-Alcoholic Fatty Liver Disease After Liver Transplantation: A Case of Nurture and Nature | 0.7 | 13 | Citations (PDF) |
| 438 | Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study | 21.2 | 277 | Citations (PDF) |
| 439 | Hepatitis C Virus Infection, Age, and Hispanic Ethnicity Increase Mortality From Liver Cancer in the United States | 6.2 | 36 | Citations (PDF) |
| 440 | Manifestations of Chronic Hepatitis C Virus Infection Beyond the Liver | 6.2 | 151 | Citations (PDF) |
| 441 | Phosphoproteomic Biomarkers Predicting Histologic Nonalcoholic Steatohepatitis and Fibrosis | 3.5 | 25 | Citations (PDF) |
| 442 | Review: Treatment options for nonalcoholic fatty liver disease | 3.5 | 121 | Citations (PDF) |
| 443 | Hepatitis C and metabolic syndrome | 3.1 | 0 | Citations (PDF) |
| 444 | A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis | 2.4 | 148 | Citations (PDF) |
| 445 | Treatment regimens for non-alcoholic fatty liver disease | 1.6 | 42 | Citations (PDF) |
| 446 | Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin | 10.6 | 40 | Citations (PDF) |
| 447 | Metabolic syndrome, non‐alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response | 4.1 | 53 | Citations (PDF) |
| 448 | Gene expression profile associated with superimposed non‐alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C | 4.1 | 15 | Citations (PDF) |
| 449 | Expression of Cytokine Signaling Genes in Morbidly Obese Patients with Non-Alcoholic Steatohepatitis and Hepatic Fibrosis | 2.4 | 47 | Citations (PDF) |
| 450 | Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver | 6.2 | 682 | Citations (PDF) |
| 451 | Independent Predictors of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease | 6.2 | 308 | Citations (PDF) |
| 452 | Nonalcoholic Fatty Liver Disease: A Practical Approach to Evaluation and Management | 3.7 | 58 | Citations (PDF) |
| 453 | Monoclonal and Polyclonal Antibodies Against the HCV Envelope Proteins | 3.7 | 6 | Citations (PDF) |
| 454 | Hepatic Stellate Cell and Myofibroblast-Like Cell Gene Expression in the Explanted Cirrhotic Livers of Patients Undergoing Liver Transplantation | 2.3 | 4 | Citations (PDF) |
| 455 | The factorial structure of the Chronic Liver Disease Questionnaire (CLDQ) | 2.1 | 50 | Citations (PDF) |
| 456 | A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH) | 2.4 | 263 | Citations (PDF) |
| 457 | Metabolic Syndrome after Laparoscopic Bariatric Surgery | 2.4 | 35 | Citations (PDF) |
| 458 | Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index | 2.6 | 62 | Citations (PDF) |
| 459 | Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study | 0.7 | 309 | Citations (PDF) |
| 460 | Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease | 3.6 | 608 | Citations (PDF) |
| 461 | Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C | 2.5 | 21 | Citations (PDF) |
| 462 | Effects of Weight Loss on Nonalcoholic Fatty Liver Disease | 3.4 | 68 | Citations (PDF) |
| 463 | Nutritional Assessments of Patients with Non-alcoholic Fatty Liver Disease | 2.4 | 53 | Citations (PDF) |
| 464 | Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome | 1.4 | 295 | Citations (PDF) |
| 465 | Evaluation and management of obesity-related nonalcoholic fatty liver disease | 4.3 | 90 | Citations (PDF) |
| 466 | Anger Experiences Among Hepatitis C Patients: Relationship to Depressive Symptoms and Health-Related Quality of Life | 3.0 | 37 | Citations (PDF) |
| 467 | Epidemiology and Natural History of NAFLD and NASH | 3.7 | 406 | Citations (PDF) |
| 468 | Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease | 3.2 | 14 | Citations (PDF) |
| 469 | The Role of Genomics and Proteomics: Technologies in Studying Non-alcoholic Fatty Liver Disease | 3.7 | 29 | Citations (PDF) |
| 470 | Pathologic Assessment of Non-alcoholic Fatty Liver Disease | 3.7 | 67 | Citations (PDF) |
| 471 | The effects of HCV infection and management on health-related quality of life | 10.6 | 167 | Citations (PDF) |
| 472 | A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis | 10.6 | 48 | Citations (PDF) |
| 473 | Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B: The hepatitis B quality of life instrument, version 1.0 | 10.6 | 75 | Citations (PDF) |
| 474 | Impact of non‐alcoholic fatty liver disease on chronic hepatitis B | 4.1 | 107 | Citations (PDF) |
| 475 | Health‐related quality of life in patients with chronic hepatitis B | 4.1 | 71 | Citations (PDF) |
| 476 | Fatigue and Health-Related Quality of Life (HRQL) in Chronic Hepatitis C Virus Infection | 2.3 | 145 | Citations (PDF) |
| 477 | Gene Expression Patterns in Hepatic Tissue and Visceral Adipose Tissue of Patients with Non-Alcoholic Fatty Liver Disease | 2.4 | 55 | Citations (PDF) |
| 478 | Depression, anemia and health-related quality of life in chronic hepatitis C | 3.6 | 130 | Citations (PDF) |
| 479 | Gene Expression of Leptin, Resistin, and Adiponectin in the White Adipose Tissue of Obese Patients with Non-Alcoholic Fatty Liver Disease and Insulin Resistance | 2.4 | 100 | Citations (PDF) |
| 480 | Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study | 2.6 | 110 | Citations (PDF) |
| 481 | The Use of Growth Factors to Manage the Hematologic Side Effects of PEG-Interferon Alfa and Ribavirin | 2.4 | 54 | Citations (PDF) |
| 482 | High Rates of Uninsured Among HCV-Positive Individuals | 2.4 | 32 | Citations (PDF) |
| 483 | Impact of Adherence on the Outcome of Antiviral Therapy for Chronic Hepatitis C | 2.4 | 45 | Citations (PDF) |
| 484 | Obesity-related Differential Gene Expression in the Visceral Adipose Tissue | 2.4 | 68 | Citations (PDF) |
| 485 | Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis | 4.1 | 105 | Citations (PDF) |
| 486 | Microarray technology in the study of obesity and non-alcoholic fatty liver disease | 4.1 | 15 | Citations (PDF) |
| 487 | Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment | 10.6 | 337 | Citations (PDF) |
| 488 | A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease | 10.6 | 223 | Citations (PDF) |
| 489 | MELD fails to measure quality of life in liver transplant candidates | 2.6 | 117 | Citations (PDF) |
| 490 | Pegylated Interferon α-2b, Ribavirin and Amantadine for Chronic Hepatitis C | 2.3 | 13 | Citations (PDF) |
| 491 | Approach to the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease | 3.7 | 29 | Citations (PDF) |
| 492 | Interactions between non-alcoholic fatty liver disease and hepatitis C viral infection | 2.7 | 3 | Citations (PDF) |
| 493 | Nonalcoholic steatohepatitis | 0.9 | 2 | Citations (PDF) |
| 494 | Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy | 10.6 | 136 | Citations (PDF) |
| 495 | Nonalcoholic fatty liver disease in patients with type 2 diabetes | 6.2 | 402 | Citations (PDF) |
| 496 | Pathologic features associated with fibrosis in nonalcoholic fatty liver disease | 2.4 | 145 | Citations (PDF) |
| 497 | Obesity and Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis C | 2.4 | 112 | Citations (PDF) |
| 498 | Nonalcoholic fatty liver disease and the epidemic of obesity. | 1.4 | 32 | Citations (PDF) |
| 499 | Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C | 10.6 | 537 | Citations (PDF) |
| 500 | Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status | 0.7 | 167 | Citations (PDF) |
| 501 | The utility of radiological imaging in nonalcoholic fatty liver disease | 1.0 | 1,883 | Citations (PDF) |
| 502 | The impact of liver disease on health-related quality of life: A review of the literature | 2.7 | 45 | Citations (PDF) |
| 503 | Nonalcoholic fatty liver disease: An agenda for clinical research | 10.6 | 219 | Citations (PDF) |
| 504 | Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults | 2.3 | 68 | Citations (PDF) |
| 505 | Chronic hepatitis C and superimposed nonalcoholic fatty liver disease | 0.0 | 139 | Citations (PDF) |
| 506 | The role of liver biopsy in chronic hepatitis C | 10.6 | 212 | Citations (PDF) |
| 507 | Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease | 2.6 | 238 | Citations (PDF) |
| 508 | Health-related quality of life in chronic liver disease: the impact of type and severity of disease | 0.7 | 298 | Citations (PDF) |
| 509 | Assessment of Utilities and Health-Related Quality of Life in Patients With Chronic Liver Disease | 0.7 | 139 | Citations (PDF) |
| 510 | Clinical Features and Natural History of Nonalcoholic Steatosis Syndromes | 3.4 | 536 | Citations (PDF) |
| 511 | A pharmacoeconomic appraisal of therapies for hepatitis B and C | 2.2 | 1 | Citations (PDF) |
| 512 | Hepatitis C, interferon alfa, and depression | 10.6 | 200 | Citations (PDF) |
| 513 | Impact of liver transplantation on health-related quality of life | 2.6 | 95 | Citations (PDF) |
| 514 | Cholestatic Liver Diseases and Health-Related Quality of Life | 0.7 | 145 | Citations (PDF) |
| 515 | Immunogenicity of Hepatitis A Vaccine in Decompensated Liver Disease | 0.7 | 94 | Citations (PDF) |
| 516 | Nonalcoholic fatty liver disease | 2.7 | 29 | Citations (PDF) |
| 517 | Hepatic iron and nonalcoholic fatty liver disease | 10.6 | 219 | Citations (PDF) |
| 518 | Evidence-based medicine: A method for solving clinical problems in hepatology | 10.6 | 13 | Citations (PDF) |
| 519 | Cost effectiveness of interferon ?2b combined with ribavirin for the treatment of chronic hepatitis C | 10.6 | 159 | Citations (PDF) |
| 520 | Outcome ofDe Novohepatitis C virus infection in heart transplant recipients | 10.6 | 82 | Citations (PDF) |
| 521 | CHRONIC VIRAL HEPATITIS IN RENAL TRANSPLANT RECIPIENTS WITH ALLOGRAFTS FUNCTIONING FOR MORE THAN 20 YEARS1,2 | 1.2 | 65 | Citations (PDF) |
| 522 | Agreement in Pathologic Interpretation of Liver Biopsy Specimens in Posttransplant Hepatitis C Infection | 2.5 | 15 | Citations (PDF) |
| 523 | Reply to Bailly, et al | 5.4 | 1 | Citations (PDF) |
| 524 | Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States | 2.3 | 3 | Citations (PDF) |
